Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Oct 08, 2021 3:27pm
206 Views
Post# 33990158

RE:RE:RE:RE:Competitive cancer drugs -CAR-T issue

RE:RE:RE:RE:Competitive cancer drugs -CAR-T issueGreat info - thanks! Have you ever asked her opinion on what TH is up to in cancer?

longterm56 wrote: Whoa! When I read this I was quite concerned, my daughter works for Kite Pharm (now owned by Gilead) where they are just completing a brand new facility to do CAR T processing (in Frederick, MD). I sent her the info to see if their facility may be affected ... here's her reply:

Oh man, that's a scary issue!
 
But luckily, Kite (currently) doesn't use this type of approach. Allogene touts "allogeneic" CAR-T, which means "other genes." With allogeneic cells, there is 1 cell line and it's supposed to work for all patients. More like traditional drugs, where all patients get the same product, which is why it's a huge issue if there's a problem with the cells.
Kite uses "autologous" CAR-T, which means "self," which is the 1 patient 1 dose approach. Since we give the patients their own cells back, just sightly modified, there's no risk of introducing this level of abnormality.
 
Obviously, allogeneic is way more cost effective and scalable, so we have lots of them in development. So it's a setback for the industry in general. But our approved drugs are both autologous.



Wino115 wrote: Thanks for further info - I didn't go beyond the headlines as you can tell. Whenever you get involved with a genetic angle, it's that much more risky scientifically. May get FDA to dig a bit deeper with all the programs just in case. 

qwerty22 wrote:

So my understand is they are trying to bring something new to CAR T, let's say CAR T plus. Take it from bespoke to off-the-shelf so it's probably not a set-back for the whole tech. Allogene were so strongly backed from their inception by Pharma and smart money, have A+ management. Shows you even with the best things go wrong. 

 

Wino115 wrote: See today that the newfangled CAR-T therapies that rely on reengineered cancer T-cells to fight the tumor had a huge stumble.  Allogene's program was put on clinical hold because a chromosonal abnormality was discovered in their CAR-T stem cells reimplanted into trial patients. 

May slow down that whole angle on using T-Cells for oncology.  Stock down 40%. May give pause to using these treatments for tumors.  Once again, a more simple to understand, less risky approach of using a receptor with a known chemo bomb may play more heavily in both research and community hospital settings.

 

 


 




<< Previous
Bullboard Posts
Next >>